IGC Pharma, Inc. IGC

IGC Company Overview

IGC Pharma, Inc. is a U.S.-based biotechnology and pharmaceutical development company focused primarily on neurodegenerative diseases, particularly Alzheimer’s disease, as well as related areas involving cognitive impairment and chronic conditions. The company operates within the biotechnology, pharmaceutical research, and clinical-stage drug development industries. Its principal activities involve developing cannabinoid-based therapeutic candidates and artificial intelligence-supported clinical research tools intended to address neurological and metabolic disorders. Public filings and investor materials identify Alzheimer’s disease therapeutics as the company’s primary strategic focus.

The company’s core revenue historically included legacy infrastructure and product activities through subsidiaries, but in recent years its strategic emphasis has shifted toward pharmaceutical research and clinical development. IGC Pharma’s lead drug candidate, IGC-AD1, is being evaluated for agitation in dementia associated with Alzheimer’s disease. The company has also referenced additional pipeline candidates targeting Parkinson’s disease symptoms, pain, and metabolic conditions. Originally incorporated as India Globalization Capital, Inc., the company evolved from a diversified holdings and infrastructure-oriented business into a life sciences-focused enterprise and later rebranded as IGC Pharma, Inc. to reflect its biotechnology strategy.